Oliver Zierau

Oliver Zierau

Auto-generated profile, based on publicly available information

Oliver Zierau

Environmental Monitoring & Endocrinology Faculty of Biology, Technische Universität Dresden Dresden Germany

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Planta Medica
Verified
Journal Article
Closed access
PDF file
OZOliver Zierau
Oliver Zierau
CMColm Morrissey
Colm Morrissey
RWR. William G. Watson
R. William G. Watson
PSPia Schwab
Pia Schwab
SKSusanne Kolba
Susanne Kolba
GVGünter Vollmer
Günter Vollmer
Naturally occurring naringenin derivatives, known for their estrogenic activity, were tested in two independent (anti-)androgen screening assays. Using a yeast-based androgen receptor assay relatively strong antiandrogen activities were demonstrated for 6-(1,1-dimethylallyl)naringenin and 8-prenylnaringenin, while the parent compound naringenin did not show recognizable antiandrogen activity. In an androgen receptor activity assay based on the analysis of prostate specific antigen (PSA) concentrations in the supernatants of treated PC3(AR)2 cells the antiandrogenic activity of 6-(1,1-dimethylallyl)naringenin was detected at concentrations of 10-5 M. 8-Prenylnaringenin or naringenin have no detectable antiandrogenic effect. In summary, for the first time we provide evidence of the antiandrogenic activity of 6-DMA-N in two independent model systems. In conclusion, we demonstrated the ability of prenylated naringenins not only to act via the estrogen receptor but also through the androgen receptor. DHT:dihydrotestosterone PSA:prostate-specific antigen Bic:bicalutamide 6-DMA-N:6-(1,1-dimethylallyl)naringenin 8-P-N:8-prenylnaringenin E2:17-β estradiol

1 January 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
OZOliver Zierau
Oliver Zierau
JHJuliane Hamann
Juliane Hamann
STSandra Tischer
Sandra Tischer
PSPia Schwab
Pia Schwab
PMPeter Metz
Peter Metz
SSStefan Scholz
Stefan Scholz

1 September 2006 in Genes & Nutrition
Verified
Journal Article
Open access
PDF file
NSN. M. Saarinen
N. M. Saarinen
CBC. Bingham
C. Bingham
SLStefano Lorenzetti
Stefano Lorenzetti
AMA. Mortensen
A. Mortensen
SMS. Mäkelä
S. Mäkelä
OZO. Zierau
O. Zierau
Phytoestrogens are naturally occurring plantderived polyphenols with estrogenic potency. They are ubiquitous in diet and therefore, generally consumed. Among Europeans, the diet is rich in multiple putative phytoestrogens including flavonoids, tannins, stilbenoids, and lignans. These compounds have been suggested to provide beneficial effects on multiple menopause-related conditions as well as on development of hormone-dependent cancers, which has increased the interest in products and foods with high phytoestrogen content. However, phytoestrogens may as well have adverse estrogenicity related effects similar to any estrogen. Therefore, the assessment of estrogenic potency of dietary compounds is of critical importance. Due to the complex nature of estrogenicity, no single comprehensive test approach is available. Instead, several in vitro and in vivo assays are applied to evaluate estrogenic potency. In vitro estrogen receptor (ER) binding assays provide information on the ability of the compound to I) interact with ERs, II) bind to estrogen responsive element on promoter of the target gene as ligand-ER complex, and III) interact between the co-activator and ERs in ligand-dependent manner. In addition, transactivation assays in cells screen for ligand-induced ERmediated gene activation. Biochemical in vitro analysis can be used to test for possible effects on protein activities and E-screen assays to measure (anti)proliferative response in estrogen responsive cells. However, for assessment of estrogenicity in organs and tissues, in vivo approaches are essential. In females, the uterotrophic assay is applicable for testing ERa agonistic and antagonistic dietary compounds in immature or adult ovariectomized animals. In addition, mammary gland targeted estrogenicity can be detected as stimulated ductal elongation and altered formation of terminal end buds in immature or peripubertal animals. In males, Hershberger assay in peri-pubertal castrated rats can be used to detect (anti)androgenic/ (anti)estrogenic responses in accessory sex glands and other hormone regulated tissues. In addition to these short-term assays, sub-acute and chronic reproductive toxicity assays as well as two-generation studies can be applied for phytoestrogens to confirm their safety in long-term use. For reliable assessment of estrogenicity of dietary phytoestrogens in vivo, special emphasis should be focused on selection of the basal diet, route and doses of administration, and possible metabolic differences between the species used and humans. In conclusion, further development and standardization of the estrogenicity test methods are needed for better interpretation of both the potential benefits and risks of increasing consumption of phytoestrogens from diets and supplements.

1 August 2006 in Toxicology Letters
Verified
Journal Article
Closed access
AFA. Friedel
A. Friedel
HGH. Geyer
H. Geyer
MKM. Kamber
M. Kamber
ULU. Laudenbach-Leschowsky
U. Laudenbach-Leschowsky
WSW. Schänzer
W. Schänzer
Patrick DielPatrick Diel
Patrick Diel

15 July 2004 in Planta Medica
Verified
Journal Article
Closed access
OZOliver Zierau
Oliver Zierau
RGRenate-B. Geis
Renate-B. Geis
STSandra Tischer
Sandra Tischer
PSPia Schwab
Pia Schwab
PMPeter Metz
Peter Metz
GVGünter Vollmer
Günter Vollmer
Phytoestrogens are discussed as candidate substances to treat symptoms related to estrogen deficiency. In in vitro experiments, the naturally occurring flavonoid 6-(1,1-dimethylallyl)naringenin (6-DMAN) emerged as one of the most potent phytoestrogenic substances. 6-DMAN is not as well characterized as other flavonoids (8-prenylnaringenin) or isoflavones (genistein). We tested 6-DMAN for the first time in vivo, in a dose-dependent three-day uterotropic assay in ovariectomized Wistar rats, using 6-DMAN at three different concentrations (1.5 mg/kg; 7.5 mg/kg and 15 mg/kg BW/d). Estradiol (E2; 10 μg/kg BW/d) and the carrier castor oil were used as positive and negative controls. 6-DMAN did not have any effect on uterine wet weight, while the positive control E2 did. In contrast, 6-DMAN stimulated uterine mRNA expression of estrogen responsive genes in ovariectomized rats. Estrogen receptor α and β mRNA were expressed in the uterus. They mediate the expression of genes with an estrogen responsive element in the promoter, e. g., complement C3 and the progesterone receptor. Therefore, we analyzed the expression of the above-mentioned genes in three different concentrations. 6-DMAN up-regulated progesterone receptor and particularly complement C3 mRNA expression however, less pronounced than E2. In conclusion, we demonstrated for the first time estrogenic activities of 6-DMAN in vivo. Surprisingly, although 6-DMAN regulated estrogen responsive gene expression, there was no uterine wet weight gain. These findings make 6-DMAN a very interesting candidate substance for further characterization, as it potentially represents a naturally occurring selective estrogen receptor modulator.

5 December 2005 in Planta Medica
Verified
Journal Article
Closed access
OZOliver Zierau
Oliver Zierau
SKSusanne Kolba
Susanne Kolba
SOSabine Olff
Sabine Olff
GVGünter Vollmer
Günter Vollmer
PDPatrick Diel
Patrick Diel
Estrogens modulate the transcription of sensitive genes either via binding of the activated ER to responsive elements in their promoter region or via binding of the activated ER to transcription factors like NFκB. In this study we have analyzed the effects of the phytoestrogens daidzein, coumestrol and genistein in promoter-specific reporter gene systems. The dose-dependent ability to stimulate an ERE-bearing reporter in MVLN breast cancer cells was compared to the dose-dependent ability to repress the IL-1β-stimulated reporter in U2OS osteosarcoma cells. Coumestrol, daidzein and genistein stimulate the expression of the ERE-dependent reporter in MVLN cells and repress the activity of the IL-6 promoter in U2OS cells in a dose-dependent manner. Interestingly, the relative potency of all phytoestrogens to repress the activity of the IL-6 promoter in U2OS cells was much higher than their potency to stimulate the ERE-dependent reporter in MVLN cells. We assume that the demonstrated promoter-specific potency therefore could be an important mechanism to explain a tissue-specific action of some of these compounds.